Pancreatic β-cell rescue in diabetes by targeting Merlin

References

• Calcutt NA, Cooper ME, Kern TS, et al. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov. 2009;8(5):417–429.
   PubMed Web of Science ®Google Scholar
• Kurrer MO, Pakala SV, Hanson HL, et al. Beta cell apoptosis in T cell-mediated autoimmune diabetes. Proc Natl Acad Sci U S A. 1997;94(1):213–218.
   PubMed Web of Science ®Google Scholar
• Mathis D, Vence L, Benoist C. Beta-cell death during progression to diabetes. Nature. 2001;414(6865):792–798.
   PubMed Web of Science ®Google Scholar
• Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102–110.
   PubMed Web of Science ®Google Scholar
• Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science. 2005;307(5708):380–384.
   PubMed Web of Science ®Google Scholar
• Cinti F, Bouchi R, Kim-Muller JY, et al. Evidence of beta-cell dedifferentiation in human type 2 diabetes. J Clin Endocrinol Metab. 2016;101(3):1044–1054.
   PubMed Web of Science ®Google Scholar
• Jeffery N, Harries LW. Beta-cell differentiation status in type 2 diabetes. Diabetes Obes Metab. 2016;18:1167–1175.
   PubMed Web of Science ®Google Scholar
• Tiwari S, Roel C, Tanwir M, et al. Definition of a Skp2-c-Myc pathway to expand human beta-cells. Sci Rep. 2016;6:28461.
   PubMed Web of Science ®Google Scholar
• Thomas HE, Kay TW. Intracellular pathways of pancreatic beta-cell apoptosis in type 1 diabetes. Diabetes Metab Res Rev. 2011;27(8):790–796.
   PubMed Web of Science ®Google Scholar
• Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol. 2009;5(4):219–226.
   PubMed Web of Science ®Google Scholar
• Johnson JD, Luciani DS. Mechanisms of pancreatic beta-cell apoptosis in diabetes and its therapies. Adv Exp Med Biol. 2010;654:447–462.
   PubMed Web of Science ®Google Scholar
• Ritzel RA, Butler AE, Rizza RA, et al. Relationship between beta-cell mass and fasting blood glucose concentration in humans. Diabetes Care. 2006;29(3):717–718.
   PubMed Web of Science ®Google Scholar
• Masini M, Bugliani M, Lupi R, et al. Autophagy in human type 2 diabetes pancreatic beta cells. Diabetologia. 2009;52(6):1083–1086.
   PubMed Web of Science ®Google Scholar
• Tomita T. Immunocytochemical localisation of caspase-3 in pancreatic islets from type 2 diabetic subjects. Pathology. 2010;42(5):432–437.
   PubMed Web of Science ®Google Scholar
• Saucedo LJ, Edgar BA. Filling out the Hippo pathway. Nat Rev Mol Cell Biol. 2007;8(8):613–621.
   PubMed Web of Science ®Google Scholar
• Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007;130(6):1120–1133.
   PubMed Web of Science ®Google Scholar
• Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer. 2013;13(4):246–257.
   PubMed Web of Science ®Google Scholar
• Ardestani A, Paroni F, Azizi Z, et al. MST1 is a key regulator of beta cell apoptosis and dysfunction in diabetes. Nat Med. 2014;20(4):385–397.
   PubMed Web of Science ®Google Scholar
• Ardestani A, Maedler K. MST1: a promising therapeutic target to restore functional beta cell mass in diabetes. Diabetologia. 2016;59(9):1843–1849.
   PubMed Web of Science ®Google Scholar
• Gao T, Zhou D, Yang C, et al. Hippo signaling regulates differentiation and maintenance in the exocrine pancreas. Gastroenterology. 2013;144(7):1543-1553, 1553.e1.
   Web of Science ®Google Scholar
• George NM, Day CE, Boerner BP, et al. Hippo signaling regulates pancreas development through inactivation of Yap. Mol Cell Biol. 2012;32(24):5116–5128.
   PubMed Web of Science ®Google Scholar
• Yuan T, Rafizadeh S, Azizi Z, et al. Proproliferative and antiapoptotic action of exogenously introduced YAP in pancreatic beta cells. JCI Insight. 2016;1(18):e86326.
   PubMed Web of Science ®Google Scholar
• George NM, Boerner BP, Mir SU, et al. Exploiting expression of Hippo effector, Yap, for expansion of functional islet mass. Mol Endocrinol. 2015;29(11):1594–1607.
   PubMed Web of Science ®Google Scholar
• Hamaratoglu F, Willecke M, Kango-Singh M, et al. The tumour-suppressor genes NF2/Merlin and expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol. 2006;8(1):27–36.
   PubMed Web of Science ®Google Scholar
• Zhang N, Bai H, David KK, et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell. 2010;19(1):27–38.
   PubMed Web of Science ®Google Scholar
• Yu J, Zheng Y, Dong J, et al. Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and expanded. Dev Cell. 2010;18(2):288–299.
   PubMed Web of Science ®Google Scholar
• Yin F, Yu J, Zheng Y, et al. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell. 2013;154(6):1342–1355.
   PubMed Web of Science ®Google Scholar
• Yuan T, Gorrepati KD, Maedler K, et al. Loss of Merlin/NF2 protects pancreatic beta-cells from apoptosis by inhibiting LATS2. Cell Death Dis. 2016;7:e2107.
   PubMed Web of Science ®Google Scholar
• Matsuda T, Zhai P, Sciarretta S, et al. NF2 activates Hippo signaling and promotes ischemia/reperfusion injury in the heart. Circ Res. 2016;119(5):596–606.
   PubMed Web of Science ®Google Scholar
• Lopez-Lago MA, Okada T, Murillo MM, et al. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol. 2009;29(15):4235–4249.
   PubMed Web of Science ®Google Scholar
• James MF, Han S, Polizzano C, et al. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol. 2009;29(15):4250–4261.
   PubMed Web of Science ®Google Scholar